Publications en collaboration avec des chercheurs de KU Leuven (25)

2024

  1. Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies

    CardioVascular and Interventional Radiology, Vol. 47, Núm. 3, pp. 310-324

  2. Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents for the Treatment of Liver Malignancy

    Journal of Vascular and Interventional Radiology, Vol. 35, Núm. 9, pp. 1253-1267.e1

  3. Skeletal muscle quality predicts overall survival in advanced liver hepatocellular carcinoma treated with SIRT and sorafenib: A subanalysis of the SORAMIC trial

    United European Gastroenterology Journal, Vol. 12, Núm. 8, pp. 1016-1027

2023

  1. Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma (Frontiers in Pharmacology, (2023), 14, (1124214), 10.3389/fphar.2023.1124214)

    Frontiers in Pharmacology

  2. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study

    JHEP Reports, Vol. 5, Núm. 2

  3. Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial

    HEPATOLOGY COMMUNICATIONS, Vol. 7, Núm. 6

  4. Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression

    European Radiology, Vol. 33, Núm. 1, pp. 493-500

  5. Predictive Factors for Adverse Event Outcomes After Transarterial Radioembolization with Yttrium-90 Resin Microspheres in Europe: Results from the Prospective Observational CIRT Study

    CardioVascular and Interventional Radiology, Vol. 46, Núm. 7, pp. 852-867

  6. Prognostic role of radiomics-based body composition analysis for the 1-year survival for hepatocellular carcinoma patients

    Journal of Cachexia, Sarcopenia and Muscle, Vol. 14, Núm. 5, pp. 2301-2309

  7. Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma

    Frontiers in Pharmacology, Vol. 14

  8. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

    ESMO Open, Vol. 8, Núm. 3

2022

  1. Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 49, Núm. 13, pp. 4716-4726

  2. Corrigendum to “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology 29 suppl. 4 (2018) v238–iv255](S0923753419317119)(10.1093/annonc/mdy308)

    Annals of Oncology

  3. Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib

    Cancer Imaging, Vol. 22, Núm. 1

  4. Prognostic Factors for Effectiveness Outcomes After Transarterial Radioembolization in Metastatic Colorectal Cancer: Results From the Multicentre Observational Study CIRT

    Clinical Colorectal Cancer, Vol. 21, Núm. 4, pp. 285-296

2021

  1. Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT)

    CardioVascular and Interventional Radiology, Vol. 44, Núm. 1, pp. 21-35

  2. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 48, Núm. 5, pp. 1570-1584

  3. Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France

    CardioVascular and Interventional Radiology, Vol. 44, Núm. 1, pp. 36-49

  4. The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases: Interim Analysis

    CardioVascular and Interventional Radiology, Vol. 44, Núm. 1, pp. 50-62

2020

  1. A multicentre, international, observational study on transarterial chemoembolisation in colorectal cancer liver metastases: Design and rationale of CIREL

    Digestive and Liver Disease, Vol. 52, Núm. 8, pp. 857-861